CELU
Price
$2.33
Change
+$0.11 (+4.95%)
Updated
Dec 20, 04:59 PM (EDT)
PRAX
Price
$75.82
Change
-$0.70 (-0.91%)
Updated
Dec 23, 11:47 AM (EDT)
79 days until earnings call
Ad is loading...

CELU vs PRAX

Header iconCELU vs PRAX Comparison
Open Charts CELU vs PRAXBanner chart's image
Celularity
Price$2.33
Change+$0.11 (+4.95%)
Volume$165
CapitalizationN/A
Praxis Precision Medicines
Price$75.82
Change-$0.70 (-0.91%)
Volume$100
CapitalizationN/A
CELU vs PRAX Comparison Chart
Loading...
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELU vs. PRAX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELU is a Hold and PRAX is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (CELU: $2.33 vs. PRAX: $76.52)
Brand notoriety: CELU and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELU: 9% vs. PRAX: 152%
Market capitalization -- CELU: $52.39M vs. PRAX: $1.43B
CELU [@Biotechnology] is valued at $52.39M. PRAX’s [@Biotechnology] market capitalization is $1.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELU’s FA Score shows that 0 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s).

  • CELU’s FA Score: 0 green, 5 red.
  • PRAX’s FA Score: 0 green, 5 red.
According to our system of comparison, CELU is a better buy in the long-term than PRAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELU’s TA Score shows that 3 TA indicator(s) are bullish while PRAX’s TA Score has 5 bullish TA indicator(s).

  • CELU’s TA Score: 3 bullish, 4 bearish.
  • PRAX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PRAX is a better buy in the short-term than CELU.

Price Growth

CELU (@Biotechnology) experienced а +4.95% price change this week, while PRAX (@Biotechnology) price change was +9.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

CELU is expected to report earnings on May 14, 2024.

PRAX is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRAX($1.43B) has a higher market cap than CELU($52.4M). PRAX YTD gains are higher at: 243.447 vs. CELU (-5.821). CELU has higher annual earnings (EBITDA): -21.59M vs. PRAX (-163.59M). PRAX has more cash in the bank: 357M vs. CELU (133K). PRAX has less debt than CELU: PRAX (1.66M) vs CELU (69.1M). CELU has higher revenues than PRAX: CELU (48.2M) vs PRAX (1.61M).
CELUPRAXCELU / PRAX
Capitalization52.4M1.43B4%
EBITDA-21.59M-163.59M13%
Gain YTD-5.821243.447-2%
P/E RatioN/AN/A-
Revenue48.2M1.61M3,003%
Total Cash133K357M0%
Total Debt69.1M1.66M4,163%
TECHNICAL ANALYSIS
Technical Analysis
CELUPRAX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
68%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
64%
Bullish Trend 4 days ago
87%
MACD
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
62%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 18 days ago
75%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 11 days ago
78%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCGSX24.350.34
+1.42%
Fidelity Series Growth Company
MMUGX22.170.29
+1.33%
MFS Utilities R1
SECAX11.160.11
+1.00%
SEI Small Cap II A (SIIT)
TQGIX17.980.13
+0.73%
T. Rowe Price Integrated Global Eq I
COSAX9.87-0.01
-0.10%
Columbia Overseas Core A

CELU and

Correlation & Price change

A.I.dvisor tells us that CELU and FATE have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELU and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELU
1D Price
Change %
CELU100%
+4.72%
FATE - CELU
27%
Poorly correlated
+1.20%
PRAX - CELU
27%
Poorly correlated
+5.05%
NVCT - CELU
27%
Poorly correlated
-3.62%
RNAC - CELU
26%
Poorly correlated
-1.30%
SAGE - CELU
26%
Poorly correlated
+12.20%
More

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with ZYME. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
+5.05%
ZYME - PRAX
38%
Loosely correlated
+4.12%
STRO - PRAX
35%
Loosely correlated
+3.30%
VERU - PRAX
35%
Loosely correlated
+3.20%
CLRB - PRAX
35%
Loosely correlated
-1.26%
MRSN - PRAX
35%
Loosely correlated
-8.05%
More